Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 38 articles:
HTML format



Single Articles


    September 2022
  1. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed     Abstract available


    July 2022
  2. BHATT A, Bhandoria G, Kepenekian V, Bakrin N, et al
    Comments on ' Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial'.
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34220.
    PubMed    


  3. KOOLE SN, Schouten PC, van Driel WJ, Sonke GS, et al
    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial".
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34219.
    PubMed    


    June 2022
  4. HUSBY A, Wohlfahrt J, Melbye M
    Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
    Int J Cancer. 2022 Jun 24. doi: 10.1002/ijc.34192.
    PubMed     Abstract available


  5. BAANDRUP L, Galanakis M, Hannibal CG, Dehlendorff C, et al
    Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis - the Extreme study.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34171.
    PubMed     Abstract available


  6. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    PubMed     Abstract available


  7. TODISCO E, Gigli F, Ronchini C, Amato V, et al
    Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.
    Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34162.
    PubMed     Abstract available


  8. SA JK, Kim J, Kang S, Kim SW, et al
    Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150.
    PubMed     Abstract available


    May 2022
  9. HARRIS HR, Guertin KA, Camacho TF, Johnson CE, et al
    Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
    Int J Cancer. 2022 May 28. doi: 10.1002/ijc.34141.
    PubMed     Abstract available


  10. KOOLE SN, Schouten PC, Hauke J, Kluin RJC, et al
    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
    Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124.
    PubMed     Abstract available


  11. JAIN S, Nadeem N, Ulfenborg B, Makela M, et al
    Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
    Int J Cancer. 2022 May 9. doi: 10.1002/ijc.34111.
    PubMed     Abstract available


    April 2022
  12. ROMANI C, Capoferri D, Reijnen C, Lonardi S, et al
    L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34035.
    PubMed     Abstract available


  13. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed     Abstract available


    March 2022
  14. CABASAG CJ, Fagan PJ, Ferlay J, Vignat J, et al
    Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020.
    Int J Cancer. 2022 Mar 23. doi: 10.1002/ijc.34002.
    PubMed     Abstract available


    February 2022
  15. LUPIA M, Melocchi V, Bizzaro F, Lo Riso P, et al
    Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33983.
    PubMed     Abstract available


    October 2021
  16. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
    Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
    PubMed     Abstract available


  17. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    PubMed     Abstract available


    September 2021
  18. HUGEN N, Kanne H, Simmer F, van de Water C, et al
    Umbilical metastases: Real-world data shows abysmal outcome.
    Int J Cancer. 2021;149:1266-1273.
    PubMed     Abstract available


  19. IYOSHI S, Yoshihara M, Nakamura K, Sugiyama M, et al
    Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33770.
    PubMed     Abstract available


    August 2021
  20. WANG T, Jake-Schoffman DE, Townsend MK, Vinci C, et al
    Early life physical activity and risk of ovarian cancer in adulthood.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33760.
    PubMed     Abstract available


    July 2021
  21. COUGHLAN AY, Testa G
    Exploiting epigenetic dependencies in ovarian cancer therapy.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33727.
    PubMed     Abstract available


    June 2021
  22. DARELIUS A, Kristjansdottir B, Dahm-Kahler P, Strandell A, et al
    Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714.
    PubMed     Abstract available


  23. PAVONE R, Pacquement H, Pasquet M, Sudour-Bonnange H, et al
    Childhood ovarian non-seminomatous germ cell tumors: A Highly Curable Disease With Few Long-Term Treatment-Related Toxicities. Results of the French TGM95 study.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33710.
    PubMed     Abstract available


    May 2021
  24. WANG T, Townsend MK, Eliassen AH, Terry KL, et al
    Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33676.
    PubMed     Abstract available


    April 2021
  25. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    PubMed     Abstract available


  26. CHRISTAKOUDI S, Pagoni P, Ferrari P, Cross AJ, et al
    Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer. 2021;148:1637-1651.
    PubMed     Abstract available


    March 2021
  27. CROSBIE EJ, Flaum N, Harkness EF, Clayton RD, et al
    Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Int J Cancer. 2021;148:1155-1163.
    PubMed     Abstract available


    February 2021
  28. YANG J, Sasamoto N, Babic A, Vitonis AF, et al
    Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses' Health Studies.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33531.
    PubMed     Abstract available


    January 2021
  29. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
    First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
    PubMed     Abstract available


  30. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    PubMed     Abstract available


    November 2020
  31. AN Y, Yang Q
    Tumor-associated macrophage targeted therapeutics in ovarian cancer.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33408.
    PubMed     Abstract available


  32. KESSOUS R, Wissing MD, Laskov I, Abitbol J, et al
    Multiple lines of chemotherapy for patients with high-grade ovarian cancer - predictors for response and effect on survival.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33395.
    PubMed     Abstract available


    October 2020
  33. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    PubMed     Abstract available


    September 2020
  34. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed     Abstract available


  35. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    PubMed     Abstract available


  36. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    PubMed     Abstract available


    February 2020
  37. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    PubMed     Abstract available


    October 2019
  38. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: